Clinical Trial Update: Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients [Phase 2]

View source ↗

Summary

Phase 2 sleep study evaluating Neu-P11 (piromelatine) for primary insomnia reported safety and efficacy results, with findings posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Neu-P11

Snippet

Sponsor: Neurim Pharmaceuticals Ltd. | Conditions: Primary Insomnia | Phase 2 | Status: COMPLETED | Results posted: 2018-06-06